Printer Friendly Version  View printer-friendly version
<< Back
Array BioPharma to Obtain $32 Million in Additional Cash From Facilities Transactions

- Proceeds to Advance Pipeline of Promising Cancer and Inflammation Drugs -

BOULDER, Colo., June 22 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has completed a series of agreements with its existing landlords for its Boulder and Longmont, Colorado facilities and with BioMed Realty Trust, Inc. (NYSE: BMR), a real estate investment trust, under which Array will assign options to purchase its facilities to BioMed. BioMed will purchase the Boulder and Longmont facilities and then lease those facilities to Array through 2016. Array expects to close the transactions during the third quarter of calendar 2006. Upon closing, the transactions are expected to add approximately $32 million in net additional cash to Array.

Array will keep its headquarters in Boulder and continue operating its 228,000 square foot research facilities in Boulder and Longmont, Colorado. In August 2005, Array announced an amendment to its Longmont facility lease, under which Array received the options to expand and to purchase the facility. At that time, Array anticipated that it would consolidate all operations in Longmont. In recent negotiations with the owner of the Boulder facility, however, Array was able to obtain improved terms and an option to purchase the buildings.

"We're pleased to have secured space that accommodates Array's long-term growth plans and the $32 million in additional capital to help us advance our promising drug pipeline," said Robert E. Conway, Chief Executive Officer, Array BioPharma. "BioMed's expertise in biotech real estate made these transactions possible, and we look forward to our long-term relationship with them."

About Array BioPharma:

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to .

About BioMed Realty Trust:

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry. Additional information is available at .

Array BioPharma's Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including the satisfaction of conditions to the closing of the transactions described above and those discussed in our annual report filed on form 10-K for the year ended June 30, 2005, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties for their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet drug objectives, including clinical trials, tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of June 22, 2006. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

SOURCE Array BioPharma Inc.

CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, /Web site:

ShareThis Copy and Paste